Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
Open Access
- 16 March 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 845887
Abstract
Novel safe, immunogenic, and effective vaccines are needed to control the COVID-19 pandemic, caused by SARS-CoV-2. Here, we describe the safety, robust immunogenicity, and potent efficacy elicited in rhesus macaques by a modified vaccinia virus Ankara (MVA) vector expressing a full-length SARS-CoV-2 spike (S) protein (MVA-S). MVA-S vaccination was well tolerated and induced S and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against SARS-CoV-2 and several variants of concern. S-specific IFNγ, but not IL-4, -producing cells were also elicited. After SARS-CoV-2 challenge, vaccinated animals showed a significant strong reduction of virus loads in bronchoalveolar lavages (BAL) and decreased levels in throat and nasal mucosa. Remarkably, MVA-S also protected macaques from fever and infection-induced cytokine storm. Computed tomography and histological examination of the lungs showed reduced lung pathology in MVA-S-vaccinated animals. These findings favor the use of MVA-S as a potential vaccine for SARS-CoV-2 in clinical trials.Keywords
This publication has 81 references indexed in Scilit:
- Pandemic Swine-Origin H1N1 Influenza Virus Replicates to Higher Levels and Induces More Fever and Acute Inflammatory Cytokines in Cynomolgus versus Rhesus Monkeys and Can Replicate in Common MarmosetsPLOS ONE, 2015
- Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesThe Journal of Infectious Diseases, 2014
- Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological studyThe Lancet Infectious Diseases, 2013
- Clinical development of Modified Vaccinia virus Ankara vaccinesVaccine, 2013
- Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature, 2012
- Barbiturate euthanasia solution‐induced tissue artifact in nonhuman primatesJournal of Medical Primatology, 2007
- Virus distribution of the attenuated MVA and NYVAC poxvirus strains in miceJournal of General Virology, 2007
- Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferretsVaccine, 2005
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.Proceedings of the National Academy of Sciences, 1993